Free tool
Oncology stocks
We cover 47 companies grouped under the Oncology theme. The median market value in the group is $99.51M. Across the group, the median move over the past trading day is 0.00%. 40% of the 43 with a 200-day average trade above it. Price change over the past year runs from −53.6% to +80.6% across the middle 80 percent of the group, with a median of −7.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
47 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 132.16 EUR | +14.19% | +47.92% | +91.49% |
| AZN.L | AstraZeneca PLC | 12,476.00 GBP | −5.00% | −8.20% | +5.65% |
| GE9.DE | Genmab A/S | 294.20 EUR | +17.26% | +9.78% | −11.12% |
| IPN.PA | Ipsen S.A. | 166.00 EUR | +1.41% | +42.98% | +40.80% |
| HCM.L | HUTCHMED (China) Limited | 179.00 GBP | +3.17% | −12.25% | −18.08% |
| NANO.PA | Nanobiotix S.A. | 35.74 EUR | +8.43% | +88.11% | +358.21% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.82% | −12.36% | −44.50% |
| PHIL.MI | Philogen S.p.A. | 23.85 EUR | +1.06% | +6.10% | +4.75% |
| EUZ.DE | Eckert & Ziegler SE | 13.18 EUR | −4.56% | −12.19% | −24.60% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.04 EUR | +0.97% | −90.91% | −90.91% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.81 EUR | +8.00% | +386.49% | +1198.08% |
| AVCT.L | Avacta Group Plc | 69.50 GBP | +0.72% | +20.87% | +26.36% |
| PRTC.L | PureTech Health plc | 121.20 GBP | +0.17% | −2.73% | −4.27% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.57% | −15.34% | −22.50% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +19.01% | +16.21% | +1.19% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +5.42% | −17.21% | −23.46% |
| SCLP.L | Scancell Holdings plc | 9.70 GBP | −2.02% | −2.02% | −7.62% |
| HPHA.DE | Heidelberg Pharma AG | 2.52 EUR | −2.70% | +0.80% | −31.15% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 74.00 PLN | −0.80% | −1.33% | +80.49% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.40 PLN | +22.67% | −32.23% | −36.99% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −79.24% |
| OSE.PA | OSE Immunotherapeutics SA | 3.21 EUR | −0.19% | −39.40% | −47.94% |
| POLB.L | Poolbeg Pharma PLC | 8.60 GBP | +36.51% | +120.51% | +164.62% |
| SAR.L | Sareum Holdings plc | 37.00 GBP | +76.19% | +117.65% | +76.19% |
| MAAT.PA | MaaT Pharma SA | 3.04 EUR | +8.96% | −45.52% | −33.91% |
| CANTA.ST | Cantargia AB (publ) | 1.91 SEK | +3.24% | −53.64% | −27.38% |
| COIL.L | Coiled Therapeutics plc | 9.50 GBP | −9.52% | −20.83% | −26.92% |
| SVE.WA | Synthaverse S.A. | 3.06 PLN | +9.29% | −20.21% | −36.25% |
| MOC.WA | Molecure S.A. | 6.03 PLN | −2.58% | −8.08% | −22.39% |
| NNG.WA | NanoGroup S.A. | 2.38 PLN | −4.80% | −11.19% | −17.36% |
| DEX.ST | Dextech Medical AB | 10.30 SEK | −0.96% | +11.35% | +26.38% |
| ALTME.PA | TME Pharma N.V. | 0.13 EUR | +113.11% | +88.41% | +25.97% |
| ABERA.ST | Abera Bioscience AB | 8.18 SEK | −2.62% | +13.61% | +1.61% |
| B8FK.DE | Biofrontera AG | 2.53 EUR | −0.78% | −0.78% | −3.07% |
| ACTI.ST | Active Biotech AB (publ) | 5.50 SEK | +6.38% | +19.57% | −62.00% |
| CRTX.L | CRISM Therapeutics Corporation | 11.50 GBP | +21.05% | +15.00% | +9.52% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | 0.32 EUR | +2.57% | −18.41% | −19.44% |
| CHOSA.ST | Chosa Oncology AB | 0.73 SEK | −14.15% | −20.00% | −9.00% |
| NFX.L | Nuformix plc | 0.16 GBP | +6.71% | −46.10% | +80.68% |
| DBP-B.ST | Double Bond Pharmaceutical International AB (publ) | 0.16 SEK | +30.42% | +16.79% | +11.79% |
| VAL.L | ValiRx plc | 0.16 GBP | +3.33% | −57.53% | −73.04% |
| ATORX.ST | Alligator Bioscience AB (publ) | 0.03 SEK | −32.46% | −91.74% | −99.27% |
| PTP.DE | Pentixapharm Holding AG | 1.85 EUR | −5.61% | +20.13% | +5.47% |
| 0VQ.DE | PureTech Health plc | 1.35 EUR | 0.00% | −12.90% | +1.50% |
| MOLN.SW | Molecular Partners AG | 3.41 CHF | +4.92% | +0.59% | +14.05% |
| T9G.DE | Vidac Pharma Holding Plc | 0.42 EUR | −9.94% | −38.68% | −38.68% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.